Search Medical Condition
Please enter condition
Please choose location

Rialto, California Clinical Trials

A listing of Rialto, California clinical trials actively recruiting patient volunteers.

RESULTS

Found (137) clinical trials

A Phase 1 Study of BLU-554 in Patients With Hepatocellular Carcinoma

This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of BLU- 554 administered orally in patients with hepatocellular carcinoma (HCC). The study consists of 2 parts, a dose-escalation part (Part 1) and an expansion part (Part ...

Phase

3.94 miles

Learn More »

A Multi-part Double Blind Study to Assess Safety Tolerability and Efficacy of LJN452 in PBC Patients

A multi-part study to assess safety, tolerability and efficacy of LJN452 in patients with primary biliary cholangitis

Phase

3.94 miles

Learn More »

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

The purpose of this study is to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when compared to a placebo.

Phase

3.94 miles

Learn More »

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

The purpose of this study is to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when compared to a placebo.

Phase

3.94 miles

Learn More »

Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis

This Phase 4, double-blind, randomized, placebo-controlled, multicenter study is being undertaken at up to 170 sites internationally to evaluate the effect of OCA on clinical outcomes in 428 subjects with PBC. The study will include a screening period of up to 8 weeks, requiring two clinic visits. Eligible participants will ...

Phase

3.94 miles

Learn More »

A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis

The main purpose of this study is to test the hypothesis that treatment with mirikizumab is superior to placebo in providing clinical benefit to participants with moderate to severe ulcerative colitis (UC). This study will also investigate how the body processes the drug.

Phase

3.94 miles

Learn More »

A Study to Evaluate the Safety Tolerability and Microbiome Dynamics of SER-287 in Subjects With Ulcerative Colitis

This is a Phase 1b multicenter, randomized, double-blind, placebo-controlled multiple dose study designed to evaluate the safety and tolerability of SER-287, and to evaluate the microbiome alterations and pharmacodynamics associated with 2 dosing regimens of SER-287 in adult subjects with mild-to-moderate ulcerative colitis (UC).

Phase

3.94 miles

Learn More »

Emricasan a Caspase Inhibitor for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis

This is a multicenter, double-blind, randomized, placebo-controlled trial involving subjects with a diagnosis of "definite NASH" with fibrosis (excluding cirrhosis) as determined by the central histopathologist. Upon successful screening, subjects will be randomized to receive either emricasan 50 mg BID or emricasan 5 mg BID or matching placebo BID.

Phase

3.94 miles

Learn More »

An Efficacy and Safety Study of LYC-30937-EC in Subjects With Active Ulcerative Colitis

Approximately 120 subjects will be randomized to receive either enteric-coated LYC-30937-EC 25 mg PO QD or matching placebo PO QD for the duration of 8 weeks. Randomization will be stratified based on previous exposure to anti-TNF agents such that at least 50% of the randomized subjects will be anti-TNF naïve ...

Phase

3.94 miles

Learn More »

Open-label Extension Study to Assess Safety and Tolerability of LYC-30937-EC in Subjects With Active Ulcerative Colitis

Subjects who complete the 8 week treatment period of the double-blind, placebo-controlled study LYC-30937-2001 will have the option of receiving LYC-30397-EC 25 mg PO QD in this open-label extension study (LYC-30937-2002). Subjects meeting eligibility criteria will enter this open-label extension trial upon completion of the LYC-30937-2001 Week 8 study procedures. ...

Phase

3.94 miles

Learn More »